Myriad Genetics Inc (MYGN)
Pretax margin
Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | -116,600 | -156,600 | -235,500 | -262,200 | -282,000 | -265,000 | -166,800 | -140,600 | -132,000 | -48,000 | -33,900 | -57,100 | -57,300 | -155,500 | -282,800 | -244,600 | -223,200 | -172,400 | -38,000 | -23,000 |
Revenue (ttm) | US$ in thousands | 817,300 | 794,900 | 766,400 | 745,400 | 731,500 | 696,200 | 691,900 | 675,200 | 820,600 | 831,200 | 839,900 | 846,300 | 666,200 | 590,100 | 564,400 | 586,600 | 627,900 | 750,000 | 801,700 | 822,500 |
Pretax margin | -14.27% | -19.70% | -30.73% | -35.18% | -38.55% | -38.06% | -24.11% | -20.82% | -16.09% | -5.77% | -4.04% | -6.75% | -8.60% | -26.35% | -50.11% | -41.70% | -35.55% | -22.99% | -4.74% | -2.80% |
September 30, 2024 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $-116,600K ÷ $817,300K
= -14.27%
Myriad Genetics Inc's pretax margin has shown a fluctuating trend over the past few quarters. The pretax margin indicates the company's efficiency in generating profits before taxes relative to its total revenue.
The data reveals that the company experienced negative pretax margins in most of the quarters, with values ranging from -50.11% in March 2021 to -4.04% in June 2022. This indicates that the company's expenses, particularly operating costs and interest payments, have been higher than its operating income during these periods.
The pretax margin deteriorated significantly in the last two quarters, reaching -19.70% in June 2024 and -14.27% in September 2024. This suggests that the company's profitability has been further impacted by factors such as declining revenues, increasing costs, or other operational challenges.
Overall, the downward trend in Myriad Genetics Inc's pretax margin indicates a potential need for the company to review its cost structure, streamline its operations, or explore revenue-generating opportunities to improve profitability and financial performance in the future.
Peer comparison
Sep 30, 2024